Glycoengineered Outer Membrane Vesicles: A Novel Platform for Bacterial Vaccines

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Price, Nancy L ^a   Goyette Desjardins, Guillaume ^b   Nothaft, Harald ^a   Valguarnera, Ezequiel ^c   Szymanski, Christine M ^a   Segura, Mariela ^b   Feldman, Mario F ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; POLYSACCHARIDE; VACCINE;

ANIMAL; CAMPYLOBACTER JEJUNI; CHICKEN; EXOSOME; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOUSE; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; CAMPYLOBACTER JEJUNI; CHICKENS; EXTRACELLULAR VESICLES; MICE; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 84964307800     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24931     Document Type: Article

References (51)

1. Levine, O. S. et al. Global status of Haemophilus influenzae type b and pneumococcal conjugate vaccines: evidence, policies, and introductions. Curr Opin Infect Dis 23, 236-41 (2010).
2. Chavez-Bueno, S. & Stull, T. L. Pediatric vaccines on the horizon. Am J Med Sci. 340, 226-31 (2010).
3. Jones, C. Vaccines based on the cell surface carbohydrates of pathogenic bacteria. An Acad Bras Cienc. 77, 293-324 (2005).
4. Seale, A. & Finn, A. What is the best way to use conjugate vaccines? Curr Opin Infect Dis 24, 219-24 (2011).
5. Bottomley, M. J., Serruto, D., Safadi, M. A. & Klugman, K. P. Future challenges in the elimination of bacterial meningitis. Vaccine 30 Suppl 2, B78-86 (2012).
6. Ellis, T. N. & Kuehn, M. J. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev 74, 81-94 (2010).
7. Bomberger, J. M. et al. Long-distance delivery of bacterial virulence factors by Pseudomonas aeruginosa outer membrane vesicles. Plos Pathog 5, e1000382 (2009).
8. Acevedo, R. et al. Bacterial outer membrane vesicles and vaccine applications. Front Immunol 5, 121 (2014).
9. Bjune, G. et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338, 1093-6 (1991).
10. Arnold, R., Galloway, Y., McNicholas, A. & O'Hallahan, J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine 29, 7100-6 (2011).
11. Holst, J. et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother 9, 1241-53 (2013).
12. Fredriksen, J. H. et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 14, 67-79, discussion 79-80 (1991).
13. Haneberg, B. et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun 66, 1334-41 (1998).
14. Feiring, B. et al. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol 13, 790-6 (2006).
15. Sierra, G. V. et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14, 195-207, discussion 208-10 (1991).
16. Norheim, G. et al. An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt. Scand J Immunol 76, 99-107 (2012).
17. Schild, S., Nelson, E. J., Bishop, A. L. & Camilli, A. Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect Immun 77, 472-84 (2009).
18. Schild, S., Nelson, E. J. & Camilli, A. Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect Immun 76, 4554-63 (2008).
19. Roberts, R. et al. Outer membrane vesicles as acellular vaccine against pertussis. Vaccine 26, 4639-46 (2008).
20. Silva, E. B. & Dow, S. W. Development of Burkholderia mallei and pseudomallei vaccines. Front Cell Infect Microbiol. 3, 10 (2013).
21. Nieves, W. et al. A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine 29, 8381-9 (2011).
22. McConnell, M. J., Rumbo, C., Bou, G. & Pachon, J. Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine 29, 5705-10 (2011).
23. Rivera, J. et al. Bacillus anthracis produces membrane-derived vesicles containing biologically active toxins. Proc Natl Acad Sci. USA 107, 19002-7 (2010).
24. Centers for Disease, C. & Prevention. Progress in introduction of pneumococcal conjugate vaccine - worldwide, 2000-2012. MMWR Morb Mortal Wkly Rep 62, 308-11 (2013).
25. Lynch, J. P. 3rd & Zhanel, G. G. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med. 16, 217-25 (2010).
26. Heikema, A. P. et al. Campylobacter jejuni capsular genotypes are related to Guillain-Barre syndrome. Clin Microbiol Infect 21, 852 e1-9 (2015).
27. Heinrichs, D. E., Monteiro, M. A., Perry, M. B. & Whitfield, C. The assembly system for the lipopolysaccharide R2 core-type of Escherichia coli is a hybrid of those found in Escherichia coli K-12 and Salmonella enterica. Structure and function of the R2 WaaK and WaaL homologs. J Biol Chem. 273, 8849-59 (1998).
28. Linton, D. et al. Functional analysis of the Campylobacter jejuni N-linked protein glycosylation pathway. Mol Microbiol 55, 1695-703 (2005).
29. Feldman, M. F. et al. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci USA 102, 3016-21 (2005).
30. Romero-Steiner, S. et al. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 13, 165-9 (2006).
31. Wacker, M. et al. Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems. Proc Natl Acad Sci USA 103, 7088-93 (2006).
32. Holst, J. et al. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 23, 2202-5 (2005).
33. Kesty, N. C. & Kuehn, M. J. Incorporation of heterologous outer membrane and periplasmic proteins into Escherichia coli outer membrane vesicles. J Biol Chem. 279, 2069-76 (2004).
34. Muralinath, M., Kuehn, M. J., Roland, K. L. & Curtiss, R. 3rd. Immunization with Salmonella enterica serovar Typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with Streptococcus pneumoniae. Infect Immun 79, 887-94 (2011).
35. Schroeder, J. & Aebischer, T. Recombinant outer membrane vesicles to augment antigen-specific live vaccine responses. Vaccine 27, 6748-54 (2009).
36. Kuipers, K. et al. Salmonella outer membrane vesicles displaying high densities of pneumococcal antigen at the surface offer protection against colonization. Vaccine 33, 2022-9 (2015).
37. Zariri, A. & van der Ley, P. Biosynthetically engineered lipopolysaccharide as vaccine adjuvant. Expert Rev Vaccines 14, 861-76 (2015).
38. Raetz, C. R. & Whitfield, C. Lipopolysaccharide endotoxins. Annu Rev Biochem 71, 635-700 (2002).
39. Galanos, C. et al. Endotoxic properties of chemically synthesized lipid A part structures. Comparison of synthetic lipid A precursor and synthetic analogues with biosynthetic lipid A precursor and free lipid A. Eur J Biochem 140, 221-7 (1984).
40. Galanos, C., Rietschel, E. T., Luderitz, O. & Westphal, O. Interaction of lipopolysaccharides and lipid A with complement. Eur J Biochem 19, 143-52 (1971).
41. van der Ley, P. et al. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 69, 5981-90 (2001).
42. Pupo, E., Hamstra, H. J., Meiring, H. & van der Ley, P. Lipopolysaccharide engineering in Neisseria meningitidis: structural analysis of different pentaacyl lipid A mutants and comparison of their modified agonist properties. J Biol Chem 289, 8668-80 (2014).
43. Arenas, J. et al. Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity. Clin Vaccine Immunol 17, 487-95 (2010).
44. van de Waterbeemd, B. et al. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 28, 4810-6 (2010).
45. Asensio, C. J. et al. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine 29, 1649-56 (2011).
46. Casella, C. R. & Mitchell, T. C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65, 3231-40 (2008).
47. Haurat, M. F. et al. Selective sorting of cargo proteins into bacterial membrane vesicles. J Biol Chem 286, 1269-76 (2011).
48. Lee, C. H. & Tsai, C. M. Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation. Anal Biochem 267, 161-8 (1999).
49. Goyette-Desjardins, G., Roy, R. & Segura, M. Murine Whole-Blood Opsonophagocytosis Assay to Evaluate Protection by Antibodies Raised Against Encapsulated Extracellular Bacteria. Methods Mol Biol 1331, 81-92 (2015).
50. Dwivedi, R., Nothaft, H., Reiz, B., Whittal, R. M. & Szymanski, C. M. Generation of free oligosaccharides from bacterial protein N-linked glycosylation systems. Biopolymers 99, 772-83 (2013).
51. Nothaft, H. et al. Diversity in the protein N-glycosylation pathways within the Campylobacter genus. Mol Cell Proteomics 11, 1203-19 (2012).